Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
drug , a cannabinoid receptor type 1 inverse agonist investigated for the treatment ofobesity but later dropped because ofside effects includingdepression andanxiety .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word taranabant.
Examples
-
Doctors at the meeting will also review a weight-loss pill called taranabant, one of two Merck drugs the company plans to submit to the FDA this year.
After a Revival, 2008
-
After first Merck stopped the development of its CB-1 antagonist taranabant and earlier this week, Sanofi-Aventis abandoned further development of rimonabant, Pfizer yesterday announced, that they too had now discontinued the development of their CB-1 antagonist CP-945,598.
Dr. Sharma’s Obesity Notes » Blog Archive » Pfizer Also Halts its CB-1 Program for Obesity 2008
-
After first Merck stopped the development of its CB-1 antagonist taranabant and earlier this week, Sanofi-Aventis abandoned further development of rimonabant, Pfizer yesterday announced, that they too had now [...]
Dr. Sharma’s Obesity Notes » Blog Archive » Bariatric Lunch Forum II 2008
-
Clearly, the decision, which comes after the recent announcement from Merck, who decided to discontinue its Phase III program for taranabant, does not bode well for this class of anti-obesity drugs.
Dr. Sharma’s Obesity Notes » Blog Archive » Rimonabant Suspended in Europe 2008
-
The preliminary results are the industry's third recent disappointment in heart-drug development after the failures of taranabant and Pfizer Inc. 's torcetrapib.
Merck Won't Seek Approval for Heart-Failure Drug This Year 2009
-
Last year, the Food and Drug Administration suggested Merck wait until 2013 for results from a large trial for the cholesterol drug Cordaptive, and Merck halted development of the experimental obesity drug taranabant because of side effects.
Merck Won't Seek Approval for Heart-Failure Drug This Year 2009
-
& Co. scrapped development of its anti-obesity drug taranabant because of side effects.
-
The scrapping of taranabant represents another setback in Merck's attempts to get new products to market amid slowing sales for some of its best-selling drugs and the looming threat of generic competition for others.
-
Merck continued to study taranabant even after it became aware of the psychiatric side effects in midstage studies, and it became evident the FDA might take a tougher stance against the class of drugs.
-
Merck's halt of taranabant suggests that this once-promising class of antiobesity drugs is coming down from its high.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.